Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 24, 2026

JDE Peet’s reports full-year results 2025

View original at globenewswire.com
JDE Peet’s reports full-year results 2025 Strong financial performance and strategic progress in volatile and challenging environment PRESS RELEASE Amsterdam, February 24, 2026 Key items1 Organic sales up +15.3%, driven by 19.5% price and -4.3% volume/mix; Reported sales up 12.3%Organic adjusted EBIT up +1.2% to EUR 1…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JDE Peet's remains committed to creating value across the entire supply chain, supporting coffee farmers in adopting sustainable practices while delivering innovative, high-quality coffee products

    80% confidence
  • The Reignite the Amazing strategy is already delivering tangible results since its launch

    80% confidence
  • Board of Directors does not propose a dividend for financial year 2025 in light of the ongoing acquisition process

    80% confidence
  • Company is preparing to build the world's best coffee company together with KDP and enter a new era of growth and innovation

    80% confidence
  • 2025 was a very good year for JDE Peet's despite unprecedented green coffee inflation, delivering strong top-line growth, increased operational profit, and generating cash in excess of 1.1 billion euro

    80% confidence
  • JDE Peet's Board of Directors fully supports and unanimously recommends the KDP offer to all shareholders for acceptance

    80% confidence
  • JDE Peet's enters 2026 from a position of strength based on strong 2025 performance and strategic momentum

    80% confidence
  • JDE Peet's is the world's leading pure-play coffee company

    80% confidence
  • Closing of the KDP acquisition offer is expected early in the second quarter of 2026, subject to satisfaction or waiver of closing conditions

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com